Published in Curr Opin Endocrinol Diabetes Obes on December 01, 2010
Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV) (BLIR-HIV) | NCT01228318
Role of T-cell reconstitution in HIV-1 antiretroviral therapy-induced bone loss. Nat Commun (2015) 1.63
HIV: inflammation and bone. Curr HIV/AIDS Rep (2012) 1.23
The Role of Inflammatory Cytokines, the RANKL/OPG Axis, and the Immunoskeletal Interface in Physiological Bone Turnover and Osteoporosis. Scientifica (Cairo) (2013) 1.20
Zinc-finger nuclease editing of human cxcr4 promotes HIV-1 CD4(+) T cell resistance and enrichment. Mol Ther (2012) 1.10
Premature decline of serum total testosterone in HIV-infected men in the HAART-era. PLoS One (2011) 0.98
HIV and bone metabolism. Discov Med (2011) 0.95
CTLA-4Ig-induced T cell anergy promotes Wnt-10b production and bone formation in a mouse model. Arthritis Rheumatol (2014) 0.86
Antiretroviral therapy in Indian setting: when & what to start with, when & what to switch to? Indian J Med Res (2011) 0.84
A cross-sectional randomised study of fracture risk in people with HIV infection in the probono 1 study. PLoS One (2013) 0.83
Serum total estradiol, but not testosterone is associated with reduced bone mineral density (BMD) in HIV-infected men: a cross-sectional, observational study. Osteoporos Int (2015) 0.82
Bone disease in HIV infection. Clin Cases Miner Bone Metab (2011) 0.81
Time of progression to osteopenia/osteoporosis in chronically HIV-infected patients: screening DXA scan. PLoS One (2012) 0.79
Common polymorphism in the LRP5 gene may increase the risk of bone fracture and osteoporosis. Biomed Res Int (2014) 0.78
Do γδ T cells predict osteonecrosis of the jaw? J Bone Miner Res (2013) 0.77
Hemin activation of innate cellular response blocks human immunodeficiency virus type-1-induced osteoclastogenesis. Biochem Biophys Res Commun (2015) 0.76
Elevated suppressor of cytokine signaling-1 (SOCS-1): a mechanism for dysregulated osteoclastogenesis in HIV transgenic rats. Pathog Dis (2014) 0.76
Hypocalcaemia, alcohol drinking and viroimmune responses in ART recipients. Alcohol (2012) 0.75
Prevalence and risk factors of low bone mineral density in Korean HIV-infected patients: impact of abacavir and zidovudine. J Korean Med Sci (2013) 0.75
Association of Blood Biomarkers of Bone Turnover in HIV-1 Infected Individuals Receiving Anti-Retroviral Therapy (ART). J AIDS Clin Res (2015) 0.75
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell (1998) 17.76
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell (1997) 15.96
Bone resorption by osteoclasts. Science (2000) 11.68
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA (2004) 10.40
Denosumab in postmenopausal women with low bone mineral density. N Engl J Med (2006) 10.02
Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature (1999) 8.23
T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature (2000) 6.49
Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS (2006) 5.58
Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med (1995) 5.27
Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med (2008) 5.14
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int (2008) 4.73
B cells in HIV infection and disease. Nat Rev Immunol (2009) 4.73
Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab (2008) 3.64
Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest (2006) 3.45
Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS (2000) 3.39
Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr (2009) 2.75
B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am J Pathol (2006) 2.56
High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. AIDS (2010) 2.49
The economic cost of hip fractures in community-dwelling older adults: a prospective study. J Am Geriatr Soc (1997) 2.40
Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. Top HIV Med (2009) 2.30
An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction. Proc Natl Acad Sci U S A (2001) 2.28
Immune response: the key to bone resorption in periodontal disease. J Periodontol (2005) 2.22
Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis (2003) 2.20
B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood (2007) 2.16
IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J Clin Invest (2006) 2.15
Continuous antiretroviral therapy decreases bone mineral density. AIDS (2009) 1.96
Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS (2007) 1.95
Short-term bone loss in HIV-infected premenopausal women. J Acquir Immune Defic Syndr (2010) 1.87
Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS (2003) 1.80
A novel T cell cytokine, secreted osteoclastogenic factor of activated T cells, induces osteoclast formation in a RANKL-independent manner. Arthritis Rheum (2009) 1.70
Mortality and serum urea and electrolytes on admission for hip fracture patients. Injury (2006) 1.62
AIDS and older Americans at the end of the Twentieth Century. J Acquir Immune Defic Syndr (2003) 1.58
OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J Immunol (1998) 1.54
The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling. J Clin Invest (2004) 1.45
Bone mass and mineral metabolism in HIV+ postmenopausal women. Osteoporos Int (2005) 1.40
Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats. Proc Natl Acad Sci U S A (2010) 1.38
Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS (2007) 1.29
First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. AIDS (2009) 1.27
Update of current therapeutic options for the treatment of postmenopausal osteoporosis. Clin Ther (2006) 1.16
Low bone mass and high bone turnover in postmenopausal human immunodeficiency virus-infected women. J Clin Endocrinol Metab (2009) 1.16
Risk factors for fracture in nonosteoporotic men and women. J Clin Endocrinol Metab (2006) 1.14
Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr (2005) 1.13
Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial. J Clin Endocrinol Metab (2007) 1.07
Increased expression of suppressor of cytokine signaling-1 (SOCS-1): A mechanism for dysregulated T helper-1 responses in HIV-1 disease. Virology (2009) 0.96
A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. AIDS (2009) 0.94
Downregulation of Gnas, Got2 and Snord32a following tenofovir exposure of primary osteoclasts. Biochem Biophys Res Commun (2009) 0.94
Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis. HIV Clin Trials (2004) 0.90
Normal human primary CD4+ T lymphocytes synthesize and release functional osteoprotegerin in vitro. Lab Invest (2007) 0.88
Bone loss in patients with HIV infection. Joint Bone Spine (2009) 0.88
Valid treatment options for osteoporosis and osteopenia in HIV-infected persons. Ann Pharmacother (2008) 0.87
Analysis of the effects of specific protease inhibitors on OPG/RANKL regulation in an osteoblast-like cell line. New Microbiol (2010) 0.86
Risk factors of osteopenia in HIV-infected women: no role of antiretroviral therapy. Maturitas (2009) 0.83
Reversal of HIV-1-associated osteoporosis with once-weekly alendronate. AIDS (2005) 0.82
No plateau for HIV/AIDS epidemic in US women. JAMA (1997) 0.81
The aging of the AIDS epidemic: emerging legal and public health issues for elderly persons living with HIV/AIDS. Elder Law J (2002) 0.78
B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood (2007) 2.16
IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J Clin Invest (2006) 2.15
Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-gamma-induced class II transactivator. Proc Natl Acad Sci U S A (2003) 1.75
A novel T cell cytokine, secreted osteoclastogenic factor of activated T cells, induces osteoclast formation in a RANKL-independent manner. Arthritis Rheum (2009) 1.70
Silencing of parathyroid hormone (PTH) receptor 1 in T cells blunts the bone anabolic activity of PTH. Proc Natl Acad Sci U S A (2012) 1.68
IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. Proc Natl Acad Sci U S A (2002) 1.65
beta2-microglobulin is a signaling and growth-promoting factor for human prostate cancer bone metastasis. Cancer Res (2006) 1.55
PTH expands short-term murine hemopoietic stem cells through T cells. Blood (2012) 1.53
Endogenous TNFalpha lowers maximum peak bone mass and inhibits osteoblastic Smad activation through NF-kappaB. J Bone Miner Res (2007) 1.42
Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats. Proc Natl Acad Sci U S A (2010) 1.38
Beta2-microglobulin promotes the growth of human renal cell carcinoma through the activation of the protein kinase A, cyclic AMP-responsive element-binding protein, and vascular endothelial growth factor axis. Clin Cancer Res (2006) 1.34
Ovariectomy disregulates osteoblast and osteoclast formation through the T-cell receptor CD40 ligand. Proc Natl Acad Sci U S A (2010) 1.33
T lymphocytes amplify the anabolic activity of parathyroid hormone through Wnt10b signaling. Cell Metab (2009) 1.32
Estrogen prevents bone loss through transforming growth factor beta signaling in T cells. Proc Natl Acad Sci U S A (2004) 1.32
Oxidative stress causes bone loss in estrogen-deficient mice through enhanced bone marrow dendritic cell activation. Proc Natl Acad Sci U S A (2007) 1.31
T cells potentiate PTH-induced cortical bone loss through CD40L signaling. Cell Metab (2008) 1.28
HIV: inflammation and bone. Curr HIV/AIDS Rep (2012) 1.23
An IL-7-dependent rebound in thymic T cell output contributes to the bone loss induced by estrogen deficiency. Proc Natl Acad Sci U S A (2005) 1.13
Inflammatory T cells rapidly induce differentiation of human bone marrow stromal cells into mature osteoblasts. J Cell Biochem (2003) 1.07
Disruption of PTH receptor 1 in T cells protects against PTH-induced bone loss. PLoS One (2010) 1.03
Zinc stimulates osteoblastogenesis and suppresses osteoclastogenesis by antagonizing NF-κB activation. Mol Cell Biochem (2011) 1.01
The intact strontium ranelate complex stimulates osteoblastogenesis and suppresses osteoclastogenesis by antagonizing NF-κB activation. Mol Cell Biochem (2011) 0.96
Bioactive silica nanoparticles promote osteoblast differentiation through stimulation of autophagy and direct association with LC3 and p62. ACS Nano (2014) 0.96
Bioactive silica-based nanoparticles stimulate bone-forming osteoblasts, suppress bone-resorbing osteoclasts, and enhance bone mineral density in vivo. Nanomedicine (2011) 0.95
HIV and bone metabolism. Discov Med (2011) 0.95
The estrogen 17beta-estradiol and phytoestrogen genistein mediate differential effects on osteoblastic NF-kappaB activity. Int J Mol Med (2009) 0.93
Ovariectomy-induced bone loss occurs independently of B cells. J Cell Biochem (2007) 0.88
Quercetin, a potent suppressor of NF-κB and Smad activation in osteoblasts. Int J Mol Med (2011) 0.88
The sclerostin-independent bone anabolic activity of intermittent PTH treatment is mediated by T-cell-produced Wnt10b. J Bone Miner Res (2014) 0.88
Inhibition of antigen presentation and T cell costimulation blocks PTH-induced bone loss. Ann N Y Acad Sci (2010) 0.87
Vitamin K2 stimulates osteoblastogenesis and suppresses osteoclastogenesis by suppressing NF-κB activation. Int J Mol Med (2010) 0.87
Ovariectomy expands murine short-term hemopoietic stem cell function through T cell expressed CD40L and Wnt10B. Blood (2013) 0.86
CTLA-4Ig-induced T cell anergy promotes Wnt-10b production and bone formation in a mouse model. Arthritis Rheumatol (2014) 0.86
Exogenous regucalcin suppresses osteoblastogenesis and stimulates adipogenesis in mouse bone marrow culture. Integr Biol (Camb) (2012) 0.83
High dose 1,25(OH)2D3 inhibits osteoblast mineralization in vitro. Int J Mol Med (2012) 0.83
T cell-expressed CD40L potentiates the bone anabolic activity of intermittent PTH treatment. J Bone Miner Res (2015) 0.81
The bone anabolic carotenoid p-hydroxycinnamic acid promotes osteoblast mineralization and suppresses osteoclast differentiation by antagonizing NF-κB activation. Int J Mol Med (2012) 0.81
A new regulator of osteoclastogenesis: estrogen response element-binding protein in bone. J Bone Miner Res (2011) 0.81
Honokiol stimulates osteoblastogenesis by suppressing NF-κB activation. Int J Mol Med (2011) 0.81
The bone anabolic carotenoid beta-cryptoxanthin enhances transforming growth factor-beta1-induced SMAD activation in MC3T3 preosteoblasts. Int J Mol Med (2009) 0.81
LONG-TERM MONITORING OF THE PHYSICOCHEMICAL PROPERTIES OF SILICA-BASED NANOPARTICLES ON THE RATE OF ENDOCYTOSIS AND EXOCYTOSIS AND CONSEQUENCES OF CELL DIVISION. Soft Mater (2013) 0.80
Suppression of NF-kappaB activation blocks osteoclastic bone resorption during estrogen deficiency. Int J Mol Med (2008) 0.80
IL-7 drives T cell-mediated bone loss following ovariectomy. Ann N Y Acad Sci (2006) 0.79
Sex steroid deficiency-associated bone loss is microbiota dependent and prevented by probiotics. J Clin Invest (2016) 0.79
Link protein N-terminal peptide binds to bone morphogenetic protein (BMP) type II receptor and drives matrix protein expression in rabbit intervertebral disc cells. J Biol Chem (2013) 0.79
Curcumin analog UBS109 prevents bone marrow osteoblastogenesis and osteoclastogenesis disordered by coculture with breast cancer MDA-MB-231 bone metastatic cells in vitro. Mol Cell Biochem (2014) 0.78
The protease inhibitors and HIV-associated bone loss. Curr Opin HIV AIDS (2016) 0.78
Elevated suppressor of cytokine signaling-1 (SOCS-1): a mechanism for dysregulated osteoclastogenesis in HIV transgenic rats. Pathog Dis (2014) 0.76
Differential CD4+ cell count increase and CD4+ : CD8+ ratio normalization with maraviroc compared with tenofovir. AIDS (2016) 0.75
Exogenous regucalcin stimulates osteoclastogenesis and suppresses osteoblastogenesis through NF-κB activation. Mol Cell Biochem (2011) 0.75